Results of the Web-Delphi process to YLV stakeholders (three rounds) (Q6701609)
From MaRDI portal
| This is the item page for this Wikibase entity, intended for internal use and editing purposes. Please use this page instead for the normal view: Results of the Web-Delphi process to YLV stakeholders (three rounds) |
Dataset published at Zenodo repository.
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | No label defined |
||
| English | Results of the Web-Delphi process to YLV stakeholders (three rounds) |
Dataset published at Zenodo repository. |
Statements
IMPACT HTA, WP7 (Methodological tools using multi-criteria value methods for HTA decision-making), Task 3 (Testing the framework with empirical applications), Results of the Web-Delphi process to TLV stakeholders (three rounds), about the views of stakeholders regarding The relevance of the following value aspects for the evaluation of new medicines in this disease context is (2020) For details on the Web-Delphi process, see: IMPACT HTA, Work Package 7 (Methodological tools using multi-criteria value methods for HTA decision-making), Task 3, Deliverable 7.3 (Testing the framework with empirical applications), Testing the IMPACT-HTA Value Framework in collaboration with HTA agencies: Case studies on Non-Small Cell Lung Cancer and Spinal Muscular Atrophy (2021), Aris Angelis (LSHTM, LSE), Mnica Oliveira (IST), Teresa Rodrigues (IST), Liliana Freitas (IST), Carlos Bana e Costa (IST), Panos Kanavos (LSE)
0 references
25 August 2021
0 references
v1
0 references